[go: up one dir, main page]

CL2021000532A1 - Vacunas peptídicas - Google Patents

Vacunas peptídicas

Info

Publication number
CL2021000532A1
CL2021000532A1 CL2021000532A CL2021000532A CL2021000532A1 CL 2021000532 A1 CL2021000532 A1 CL 2021000532A1 CL 2021000532 A CL2021000532 A CL 2021000532A CL 2021000532 A CL2021000532 A CL 2021000532A CL 2021000532 A1 CL2021000532 A1 CL 2021000532A1
Authority
CL
Chile
Prior art keywords
cancer
polypeptides
treatment
pharmaceutical compositions
peptides
Prior art date
Application number
CL2021000532A
Other languages
English (en)
Spanish (es)
Inventor
Julianna Liszewicz
Levente Molnar
Eniko Toke
József Toth
Orsolya Lorincz
Zsolt Csiszovszk
Eszter Somogyi
Katalin Pantya
Mónika Megyesi
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1814367.7A external-priority patent/GB201814367D0/en
Priority claimed from GBGB1814365.1A external-priority patent/GB201814365D0/en
Priority claimed from GBGB1814364.4A external-priority patent/GB201814364D0/en
Priority claimed from GBGB1814366.9A external-priority patent/GB201814366D0/en
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of CL2021000532A1 publication Critical patent/CL2021000532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
CL2021000532A 2018-09-04 2021-03-04 Vacunas peptídicas CL2021000532A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1814367.7A GB201814367D0 (en) 2018-09-04 2018-09-04 Peptide Vaccines
GBGB1814365.1A GB201814365D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814364.4A GB201814364D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814366.9A GB201814366D0 (en) 2018-09-04 2018-09-04 Peptide vaccines

Publications (1)

Publication Number Publication Date
CL2021000532A1 true CL2021000532A1 (es) 2021-09-24

Family

ID=67874441

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021000532A CL2021000532A1 (es) 2018-09-04 2021-03-04 Vacunas peptídicas
CL2024001738A CL2024001738A1 (es) 2018-09-04 2024-06-11 Vacunas peptídicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024001738A CL2024001738A1 (es) 2018-09-04 2024-06-11 Vacunas peptídicas

Country Status (16)

Country Link
US (2) US11666644B2 (fr)
EP (1) EP3846845A1 (fr)
JP (2) JP7642530B2 (fr)
KR (1) KR20210086612A (fr)
CN (1) CN113329761A (fr)
AU (1) AU2019334437A1 (fr)
BR (1) BR112021004071A2 (fr)
CA (1) CA3110760A1 (fr)
CL (2) CL2021000532A1 (fr)
CO (1) CO2021004019A2 (fr)
IL (1) IL281224A (fr)
MA (1) MA53543A (fr)
MX (1) MX2021002449A (fr)
SA (1) SA521421371B1 (fr)
SG (1) SG11202101888YA (fr)
WO (1) WO2020048990A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7751374B2 (ja) 2017-03-03 2025-10-08 トレオス バイオ リミテッド ペプチドワクチン
AU2019334437A1 (en) 2018-09-04 2021-03-18 Treos Bio Limited Peptide vaccines
AU2020302285A1 (en) * 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022233956A1 (fr) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant de manière spécifique à prame
KR102846817B1 (ko) * 2023-06-28 2025-08-18 주식회사 이온셀 Ct83 항원에 대한 인간 단클론 항체 및 이의 용도
CN119751578A (zh) * 2025-03-10 2025-04-04 南昌大学第一附属医院 结直肠癌新抗原免疫多肽及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
EP0914142B9 (fr) 1996-03-11 2012-01-04 Epimmune Inc. Peptides presentant une affinite augmente pour au moins trois molecules de type hla-a3
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
AU768834B2 (en) 1998-04-01 2004-01-08 Yale University A method for selectively modulating the interactions between survivin and tubulin
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
EP1235841A4 (fr) * 1999-12-10 2006-04-12 Epimmune Inc Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CN1691964A (zh) 2002-09-06 2005-11-02 曼康公司 表位序列
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
CA2522379C (fr) 2003-04-10 2012-10-23 Chiron Corporation Le coronavirus du syndrome respiratoire aigu grave
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
KR101216655B1 (ko) 2003-11-19 2013-01-02 수르벡 에이피에스 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도
CN101434647A (zh) 2004-01-20 2009-05-20 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
AU2005250170A1 (en) 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
WO2006014579A2 (fr) 2004-07-08 2006-02-09 The Regents Of California Renforcement de la presentation d'un antigene de classe 1 avec des sequences synthetiques
EP1842911A4 (fr) 2005-01-25 2008-12-10 Nec Corp Peptides se liant au hla, fragments d'adn codant pour lesdits peptides et vecteurs recombinants
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
CN100402554C (zh) 2005-02-25 2008-07-16 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
JP2009531303A (ja) 2006-03-01 2009-09-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ リンパ球枯渇剤をｃｔｌおよびサイトカインと組合せる癌処置
CA2665816C (fr) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Vaccins a multiples epitopes specifiques a un antigene
CA2700573C (fr) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
KR20090060450A (ko) 2006-10-04 2009-06-12 얀센 파마슈티카 엔.브이. 불활성화 인공 항원 제시 세포의 제조 및 세포 치료법에서 이들의 용도
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
EP2042600A1 (fr) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique Epitope de cellule CD4+ T publique et immunogène de la protéine tat vih et ses applications
WO2009123188A1 (fr) 2008-03-31 2009-10-08 株式会社バイオイミュランス Peptide partiel de survivine présenté sur une molécule du cmh classe ii et son utilisation
NO2119726T3 (fr) 2008-05-14 2015-05-23
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (fr) 2008-10-01 2011-06-29 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
US20120244145A1 (en) 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (fr) 2010-10-14 2012-04-19 The Ohio State University Research Foundation Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l)
EP2688904B1 (fr) 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides présentant une affinité pour les protéines de choc thermique (hsp) et complexes associés à une hsp (hacs) et leur utilisation en diagnostic et en thérapie
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US20140234350A1 (en) 2013-02-14 2014-08-21 Cedars-Sinai Medical Center Ovarian cancer vaccines and vaccination methods
US10022441B2 (en) 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
EP3134104B1 (fr) 2014-04-25 2018-12-26 Tria Bioscience Corp. Compositions de support d'haptène synthétique et procédés
WO2016040900A1 (fr) 2014-09-14 2016-03-17 Washington University Vaccins anticancéreux personnalisés, et procédés correspondants
US20160074489A1 (en) 2014-09-15 2016-03-17 Regen Biopharma, Inc Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation
CA2969231C (fr) 2014-12-03 2021-06-08 Verik Bio, Inc. Identification, selection et utilisation d'epitopes de cellule t a haut potentiel curatif
CN107531736B (zh) 2015-01-06 2022-04-15 免疫疫苗科技公司 脂质a模拟物、其制备方法和用途
WO2016172722A1 (fr) 2015-04-23 2016-10-27 Nantomics, Llc Néo-épitopes de cancer
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US20180162913A1 (en) 2015-05-01 2018-06-14 Immunovaccine Technologies Inc. Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
EP3313431B1 (fr) * 2015-06-29 2023-11-15 OSE Immunotherapeutics Procédé permettant d'induire une réponse de mémoire t précoce avec un vaccin anti-tumeur à peptides courts
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US9790562B2 (en) 2015-09-30 2017-10-17 Augusta University Research Institute, Inc. Compositions and methods for the detection or treatment of uterine leiomyosarcoma
CA3003251A1 (fr) 2015-10-12 2017-04-20 Nantomics, Llc Systemes, compositions, et procedes de decouverte de msi et de neoepitopes qui prevoient la sensibilite a des points de controle immunitaires
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
CA3005127C (fr) 2015-11-18 2023-01-24 Immunovaccine Technologies Inc. Systemes adjuvant et compositions vaccinales sans eau comprenant un adjuvant de type polyi:c et un adjuvant lipidique
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
CA3023560A1 (fr) 2016-05-13 2017-11-16 Mbl International Corp. Systeme et procede d'echange de peptides
CN110352067B (zh) 2016-10-07 2024-09-24 得克萨斯州大学系统董事会 Hla限制性vgll1肽及其用途
WO2018102585A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes
TWI796314B (zh) 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
EP3370065A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Peptides immunogènes
JP7751374B2 (ja) 2017-03-03 2025-10-08 トレオス バイオ リミテッド ペプチドワクチン
EP3369431A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Vaccin
CA3069019A1 (fr) 2017-07-10 2019-01-17 Immunovaccine Technologies Inc. Compositions pharmaceutiques, procedes de preparation utilisant des particules de vesicules lipidiques de taille definie, et leurs utilisations
CA3081710A1 (fr) 2017-11-08 2019-05-16 Advaxis, Inc. Peptides heteroclitiques immunogenes issus de proteines associees au cancer et procedes d'utilisation de ces peptides
JP7103726B2 (ja) 2017-11-09 2022-07-20 イミューノヴァクシーン テクノロジーズ インコーポレイテッド 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用
CA3086923A1 (fr) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Proteines se liant a l'antigene ciblant des antigenes partages
CN112512538A (zh) 2018-05-18 2021-03-16 国家儿童医疗中心 改进的靶向t细胞疗法
WO2019222762A1 (fr) 2018-05-18 2019-11-21 Children's National Medical Center Compositions de thérapie cellulaire améliorées pour patients ayant subi une transplantation de cellules souches hématopoïétiques
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
AU2019334437A1 (en) 2018-09-04 2021-03-18 Treos Bio Limited Peptide vaccines
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
AU2019383785A1 (en) 2018-11-19 2021-06-03 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
EP3908293A4 (fr) 2019-01-07 2023-01-11 Children's National Medical Center Compositions de lymphocytes t activées ex vivo et leurs procédés d'utilisation
CA3126064A1 (fr) 2019-01-07 2020-07-16 Children's National Medical Center Therapie amelioree a lymphocytes t cibles pour le traitement du myelome multiple
CA3153179A1 (fr) 2019-10-16 2021-04-22 Immunovaccine Technologies Inc. Formulations d'emulsion a phase continue aqueuse pour l'administration d'agents actifs ou therapeutiques
CN110713546B (zh) 2019-10-31 2021-04-20 中国医科大学附属第一医院 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Also Published As

Publication number Publication date
BR112021004071A2 (pt) 2021-06-01
AU2019334437A1 (en) 2021-03-18
JP7642530B2 (ja) 2025-03-10
SG11202101888YA (en) 2021-03-30
SA521421371B1 (ar) 2024-06-06
US20230102031A1 (en) 2023-03-30
US20240000911A1 (en) 2024-01-04
JP2021536487A (ja) 2021-12-27
JP2024097033A (ja) 2024-07-17
MA53543A (fr) 2021-07-14
CA3110760A1 (fr) 2020-03-12
CN113329761A (zh) 2021-08-31
IL281224A (en) 2021-04-29
KR20210086612A (ko) 2021-07-08
CO2021004019A2 (es) 2021-07-19
EP3846845A1 (fr) 2021-07-14
WO2020048990A1 (fr) 2020-03-12
CL2024001738A1 (es) 2024-11-15
MX2021002449A (es) 2021-08-05
US11666644B2 (en) 2023-06-06

Similar Documents

Publication Publication Date Title
CO2019010698A2 (es) Vacunas de peptidos
CL2021000532A1 (es) Vacunas peptídicas
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
CO2021004028A2 (es) Proceso para la preparación de composiciones de vacunas
MX2019008350A (es) Formulaciones de anticuerpos de her2 subcutáneas.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
MX2016009809A (es) Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
EP4253419A3 (fr) Un vaccin en combinaison avec un inhibiteur de point de contrôle immunitaire pour le traitement de cancer
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)
AR102555A1 (es) Inmunoterapia t específica de múltiples péptidos terapéuticos para el tratamiento de metástasis cerebral
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
HRP20200160T1 (hr) Peptidi desmogleina 3 za pemphigus vulgaris
BR112017027653A2 (pt) método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos
CL2018002438A1 (es) Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna.
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
EA202190670A1 (ru) Пептидные вакцины